

Rationale

Dystonia and Parkinson's disease have traditionally been viewed as distinct movement disorders. However, compelling clinical and experimental evidence suggest that these diseases can share, at least to some extent, common pathogenic features. As for the past editions of this biennial meeting, held from 2007 to 2017, the next workshop to be held in September 2019, will be focused on clinical and scientific aspects bridging dystonia and Parkinson's disease (PD). Primary aim of this edition of the biennial workshop will be to provide a complete overview of these potential interactions, focusing on "Cellular and molecular targets for novel therapeutics".

SPEAKERS AND CHAIRS

Albanese Alberto	Gardoni Fabrizio	Pierantozzi Mariangela
Bentivoglio Anna Rita	Gonzalez-Alegre Pedro	Pisani Antonio
Bezard Erwan	Goodchild Rose	Roze Emmanuel
Bhatia Kailash	Hess Ellen J.	Salt Tom
Blandini Fabio	Jinnah Hyder A.	Sciamanna Giuseppe
Bonsi Paola	Klopstock Thomas	Standaert David G.
Bragg Cris	Lang Anthony E.	Stefani Alessandro
Calabresi Paolo	Leuzzi Vincenzo	Teller Jan
Capetian Philipp	Mencacci Niccolò	Valente Enza Maria
Calakos Nicole	Mercuri Nicola Biagio	Vidailhet Marie
Carecchio Miryam	Padovani Alessandro	
Cruz Lilian	Perlmutter Joel	

WORKSHOP PLANNER

Prof. Antonio Pisani

Professore Associato Neurologia – Università degli Studi di Roma Tor Vergata

LOCAL ORGANIZING COMMITTEE

Bonsi Paola - Imbriani Paola - Martella Giuseppina - Meringolo Maria
Ponterio Giulia - Schirinzi Tommaso - Sciamanna Giuseppe - Tassone Annalisa

GENERAL INFORMATION

The official language of the Congress is English.
No simultaneous translation will be available.

CONGRESS VENUE

Nobile Collegio Chimico Farmaceutico
Via in Miranda, 10 | 00186 Rome | Tel. 06 679 21 23

E.C.M. 680 - 267453

Has assigned n. 11 CREDITS

Biologo - Chimico - Fisioterapista - Infermiere - Infermiere pediatrico - Tecnico di neurofisiopatologia - Terapista della neuro e psicomotricità dell'età evolutiva Medico Chirurgo (Farmacologia e Tossicologia Clinica, Genetica Medica, Medicina Fisica e Riabilitazione, Neurochirurgia, Neurofisiopatologia, Neurologia, Neuropsichiatria Infantile, Neuroradiologia, Pediatria, Psichiatria)

TRAINING OBJECTIVES

DOCUMENTAZIONE CLINICA, PERCORSI CLINICO-ASSISTENZIALI DIAGNOSTICI E RIABILITATIVI, PROFILI DI ASSISTENZA-PROFILI DI CURA

PROVIDER ECM AND ORGANIZING SECRETARIAT

DOTCOM SRL Provider ECM ID 680

Via Flaminia, 54 | 00196 Roma

Tel. +39 06 4061370 | Fax +39 06 3242600

E-mail: info@dotcomeventi.com | www.dotcomeventi.com

Registration FEE € 150.00 (22% vat not included) (PhD students, Trainees free of charge)

Participation's registration fee includes: admission to the scientific sessions from 18 to 19 september; congress documents, coffee breaks & lunches.

Registration form can be downloaded from the website: www.dotcomeventi.com

CERTIFICATE OF ATTENDANCE

At the end of the congress, a certificate of attendance will be given to participants on request at the Registration Desk.

With unrestricted grants from

Main sponsor **abbvie**

Other sponsors

Bial

Chiesi
People and ideas for innovation in healthcare

LUSOFARMACO

ucb Inspired by patients.
Driven by science.

Zambon



Under the patronage of



7th Biennial Workshop on Dystonia and Parkinson's Disease:

*“Cellular and molecular targets
for novel therapeutics”*

ROME

18-19

September 2019



Nobile Collegio Chimico Farmaceutico, Rome, Italy

Supported by

THE BACHMANN-STRAUSS
Dystonia & Parkinson Foundation, Inc.

**DYSTONIA
MEDICAL
RESEARCH
FOUNDATION**

**International Parkinson and
Movement Disorder Society**

**Parkinson's
Disease
Foundation**
A division of the Parkinson's Foundation

DAY 1 - September 18

- 12.00 Registration
- 12.30 Welcome from authorities
- 12.45 Welcoming remarks: A. Pisani, B. Strauss, J. Teller

DEBATE
Chairs: A. Albanese, J. Perlmutter

- 13.00 Are the clinical features of isolated dystonia the same as those of dystonia in Parkinson's disease? K. Bhatia, A.E. Lang
- 13.45 Discussion

SESSION 1
DYSTONIA AND PD: NEW GENES, NEW THERAPEUTIC TARGETS?
(ARE GENE PRODUCTS LEADING TO DISCOVERIES FOR NOVEL THERAPEUTIC AGENTS?)

Chairs: R. Goodchild, E. M. Valente

- 14.00 New genes for rare hyperkinetic movement disorders: what are we learning about molecular pathophysiology of striatal disorders? - N. Mencacci
- 14.20 When genetics meet surgery: DBS outcome in genetically-determined dystonia and PD - M. Carecchio
- 14.40 Shared and unique pathophysiological features of PD and DOPA-responsive dystonia - E. J. Hess
- 15.00 Discussion

SESSION 2
Chairs: A. Bentivoglio, M. Pierantozzi

- 15.20 Poster session (Data Blitz) - Scientific contribution in original on topics discussed during the event and evaluated by the scientific committee
- 16.00 Discussion of the poster presentation
- 16.30 Concluding remarks

DAY 2 - September 19

- 08.00 Registration

DEBATE
Chairs: E. Bezard, M. Vidailhet

- 08.30 Dopamine receptors in dystonia and levodopa-induced dyskinesias: distinct targets? P. Bonsi, D. G. Standaert
- 09.30 Discussion

SESSION 3
NOVEL CELLULAR AND MOLECULAR TARGETS
(DO DYSTONIA TARGETS APPLY FOR PD?)
Chairs: F. Blandini, H. A. Jinnah

- 09.50 eIF2alpha signaling in dystonia - N. Calakos
- 10.10 ERK signaling in the striatum: a point of convergence for hyperkinetic disorders? - P. Gonzalez-Alegre
- 10.30 Differential modifications of AMPA and NMDA receptor subunits at striatal synapses in PD and dystonia - F. Gardoni
- 10.50 Discussion
- 11.10 Coffee break

SESSION 4
NOVEL TECHNOLOGIES FOR DYSTONIA AND PD RESEARCH
Chairs: C. Bragg, P. Calabresi

- 11.40 Patient-derived vs. isogenic neural stem cell models - P. Capetian
- 12.10 Role of Globus Pallidus in Dystonia: Optogenetic strategies to unveil the altered neural circuits - G. Sciamanna
- 12.40 CRISPR/Cas9 for allele-specific editing in DYT1 iPSCs - L. Cruz
- 13.10 Discussion
- 13.30 Light Lunch

SESSION 5
MOLECULAR TARGETS FOR DYSTONIA AND PD:
CLUES FROM TREATABLE INHERITED DISORDERS
Chairs: V. Leuzzi, A. Padovani

- 14.30 Parkinsonism in Children - V. Leuzzi
- 14.50 Triheptanoin for the treatment of brain energy deficit: from Glut1 deficiency to other movement disorders - E. Roze
- 15.10 Heavy metals: possible therapy with chelating agents - T. Klopstock
- 15.50 Discussion

SESSION 6
ROUND-TABLE

- 16.10 Novel drugs for dystonia and PD
E. Bezard, N. B. Mercuri, T. Salt, A. Stefani, J. Teller
- 17.40 Concluding remarks and CME evaluation

NO C.M.E.

- 18.00 Orphan drugs for orphan receptors? R. Mills, G. Lang, R. Lütjens, T. Salt